Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

AbbVie Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (149)
Cancellation by sponsor (70)
Australian Public Assessment Report (AusPAR) (21)
Prescription medicine registration (20)
Designation or determination (6)
Prescription medicine evaluation (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2024 (20)
2023 (27)
2022 (14)
2021 (14)
2020 (20)
2019 (25)
2018 (14)
2017 (29)
2016 (5)
2015 (19)
2014 (29)
2013 (4)
2012 (4)
2011 (4)
2010 (7)
2009 (4)
2008 (4)
2007 (1)
2006 (4)
2005 (4)
2003 (3)
2002 (2)
2001 (4)
1999 (1)
1998 (1)
1997 (1)
1996 (1)
1994 (2)
1991 (5)

Results for "[search-keyword]"

Search

Sponsor content

272 result(s) found, displaying 131 to 140

VENCLEXTA venetoclax 50 mg film-coated tablet blister pack (267444)

5 January 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for VENCLEXTA venetoclax 50 mg film-coated tablet blister pack.
VENCLEXTA venetoclax 100 mg film-coated tablet blister pack (267442)

5 January 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for VENCLEXTA venetoclax 100 mg film-coated tablet blister pack.
Abbvie Pty Ltd - Lubricant, eye (283395)

12 December 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - Lubricant, eye.
LUCRIN leuprorelin acetate 5mg/mL injection multidose vial Cancelled under Section 30(1)(c) of the Act

17 April 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd- Syringe, hypodermic, metered-delivery Cancelled under Section 41GL(d) of the Act

17 April 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd - Medicine administration kit, percutaneous, medicated, reusable Cancelled under Section 41GL(d) of the Act

17 April 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
Abbvie Pty Ltd- Applicator, antiseptic Cancelled under Section 41GL(d) of the Act

17 April 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tablets and dasabuvir (as sodium salt) 250mg tablets composite pack blister pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tab and dasabuvir (Na) 250mg tab and ribavirin 600mg tab, blisters composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tabs and dasabuvir (Na) 250mg tabs and ribavirin 200mg tabs, bottles composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd

Pages

First page
Previous page
…
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.